Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 14/20 | 0.51 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.51 |
| ▸ | NPC1 | O15118 | 2/20 | 0.43 |
| ▸ | RAB9A | P51151 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.41 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.41 |
| ▸ | FBP1 | P09467 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2734523 | 0.90 | TRPV1 (0.49) | TRPV1OPRM1 | |
| SCHEMBL13613609 | 0.89 | TRPV1 (0.51) | TRPV1OPRM1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL13613606 | 0.88 | TRPV1 (0.59) | TRPV1OPRM1 | |
| SCHEMBL13613611 | 0.87 | TRPV1 (0.56) | TRPV1OPRM1 | |
| SCHEMBL13613644 | 0.87 | TRPV1 (0.49) | TRPV1OPRM1 | |
| SCHEMBL13613635 | 0.87 | TRPV1 (0.54) | TRPV1OPRM1 | |
| SCHEMBL13613633 | 0.87 | ALDH1A1 (0.50) | TRPV1OPRM1SMN1; SMN2ROCK2 | |
| SCHEMBL2734756 | 0.86 | TRPV1 (0.50) | TRPV1OPRM1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL2734516 | 0.86 | TRPV1 (0.47) | TRPV1OPRM1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL13613630 | 0.85 | TRPV1 (0.61) | TRPV1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612113-B2 | Such as N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(7-hydroxy-5,6,7,8-tetrahydro-1-naphthalenyl)urea; vanilloid receptor antagonists; for treatment of urge urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, COPD | XENTION LIMITED (GB) | 2009-11-03 | — | — | US | disclosed |
| US-7612113-B2 | Such as N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(7-hydroxy-5,6,7,8-tetrahydro-1-naphthalenyl)urea; vanilloid receptor antagonists; for treatment of urge urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, COPD | XENTION LIMITED (GB) | 2009-11-03 | — | — | US | disclosed |